Please login to the form below

Not currently logged in
Email:
Password:

Abbott and Zydus emerging markets deal

Abbott has entered into an agreement with India's Zydus Cadila relating to a portfolio of products that it will commercialise in 15 emerging markets

Abbott has entered into a licensing and supply agreement with India-based Zydus Cadila. The deal relates to a portfolio containing at least 24 Zydus products, which Abbott will commercialise in 15 key emerging markets where Abbott already has a strong and growing presence.

As part of the agreement, more than 40 additional Zydus products could be added to the collaboration deal. The partnership covers medicines for pain, cancer and cardiovascular, neurological and respiratory diseases. Product launches are expected to commence in early 2012.

Abbott has also created a stand-alone Established Products Division (EPD) that will concentrate on expanding access to non-US markets, particularly emerging markets, for Abbott's established pharmaceutical products.

"Our new Established Products Division, with $5bn in sales, wll focus on expanding our presence and product offerings in the world's fastest-growing emerging markets," said Olivier Bohuon, executive vice president, Pharmaceutical Products Group, Abbott.

Abbott has a large portfolio of branded generics, which the company has built up over the past 10 years, Abbott's acquisition of Solvay earlier this year helped the company to gain significant critical mass in key emerging markets.

12th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics